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ABSTRACT
Stable mixed donor/host chimerism has been reliably established in dogs given a sublethal dose (2 Gy) of total
body irradiation (TBI) before and immunosuppression with mycophenolate mofetil (MMF) or rapamycin
combined with cyclosporine (CSP) after marrow transplantation from dog leukocyte antigen (DLA)-identical
littermates (hematopoietic cell transplantation [HCT]). When TBI was reduced to 1 Gy, only transient
engraftment was observed. Here we investigated whether stable engraftment after 1-Gy TBI could be
accomplished by reducing host-versus-donor immune responsiveness through preceding CD154 blockade and
infusion of donor peripheral blood mononuclear cells (PBMCs). We found that the anti-human CD154
antibody, 5c8, cross-reacted with canine lymphocytes and blocked alloimmune responses in vitro. Based on
pharmacokinetic studies, 6 dogs received a single intravenous injection of 5 mg/kg anti-CD154 antibody (on
day 5), followed 1 day later by donor PBMCs. On day 0, the dogs were given 1 Gy of TBI and underwent
DLA-identical marrow grafts. Postgraft immunosuppression consisted of MMF and CSP. All 6 dogs demon-
strated initial engraftment; 3 dogs sustained the engraftment for >26 weeks, whereas 3 dogs rejected their
grafts, after 9, 22, and 24 weeks, and survived with autologous recovery. Graft survival was significantly
improved over that in 11 historical controls conditioned with 1-Gy TBI and given either MMF or rapamycin
with CSP after HCT, all of which rejected their grafts between 3 and 12 weeks (P  .03). Preceding donor
PBMC infusion and CD154 blockade improved survival of DLA-identical marrow grafts after 1-Gy TBI.
© 2007 American Society for Blood and Marrow Transplantation
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DNTRODUCTION
Sustained engraftment of dog leukocyte antigen
DLA)-identical littermate marrow was the rule in
ogs conditioned with a nonmyeloablative dose of 2
y of total body irradiation (TBI) and given short
ourses of postgraft immunosuppression with either
ycophenolate mofetil (MMF) or rapamycin along
ith cyclosporine (CSP) [1,2]. However, uniform
raft rejections were seen when TBI conditioning was
ecreased to 1 Gy. In contrast, most dogs showed
ustained engraftment when 1-Gy TBI was preceded
y intravenous injections of both peripheral blood
ononuclear cells (PBMCs) from the marrow donor g
64nd T-cell costimulatory blocker CTLA4-Ig [3]. Here
e used 1-Gy TBI conditioning to evaluate whether
lockade of another costimulatory pathway—the in-
eraction between CD40 and CD154—was equally
ffective in enhancing marrow engraftment. Blockade
f this pathway has been successful in murine models
f hematopoietic stem cell transplantation and differ-
nt animal models of solid organ transplantation [4-6].
ATERIALS AND METHODS
ogs
Litters of beagle, mini-mongrel, basenji, and
olden retriever crossbreeds, either raised at the Fred
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DLA-Identical Marrow Transplantation in Dogs 165utchinson Cancer Research Center (FHCRC) or
urchased from commercial kennels, were assessed for
isease and enrolled in a veterinary preventive medi-
ine program against worms, distemper, parvovirus,
denovirus type 2, parainﬂuenza virus, corona virus,
abies, and canine papillomavirus. The dogs were age
-24 months and weighed 8.1-15.1 kg (median, 9.6
g).
The study was approved by the FHCRC’s Insti-
utional Animal Care and Use Committee, which is
ccredited by the Association for Assessment and Ac-
reditation of Laboratory Animal Care International.
LA-identical littermates were selected as donor–
ecipient pairs on the basis of matching for highly
olymorphic microsatellite markers within DLA class
and class II regions [7], which was conﬁrmed by
LA-DRB1 sequencing [8].
onoclonal Antibody 5c8
The hybridoma cell line obtained from American
ype Culture Collection (Manassas, VA) produced
he mouse anti-human CD154 monoclonal antibody
mAb) 5c8 [9]. Hybridoma cells were cultivated ac-
ording to the guidelines of the provider. The mAb
as puriﬁed from supernatant and checked for endo-
oxin by the FHCRC biologic production facility.
ndotoxin-free antibody was diluted in phosphate-
uffered saline (PBS) without calcium and magnesium
t a concentration of 1.4-1.5 mg/mL and immediately
rozen at 70°C until use.
ross-Reactivity with Canine CD154
Cross-reactivity of the mAb 5c8 was determined
y ﬂow cytometry using canine lymphocytes stimu-
ated with 4-phorbol 12-myristate 13-acetate (PMA)
nd ionomycin. For these studies, canine PBMCs
ere separated from 20-30 mL of blood using Ficoll
radient centrifugation (speciﬁc density, 1.074 g/dL).
he cells were washed, counted, and resuspended in
PMI medium supplemented with 10% heat-inacti-
ated canine serum, 2 mmol of L-glutamine, 100
/mL of penicillin, 100 g/mL of streptomycin, and
0 mol of -mercaptoethanol at a concentration of
 106 cells per mL. Then 1-mL cell suspension
amples were plated on a 24-well plate (1 sample per
late). Ionomycin and PMA were added to the lym-
hocyte culture at ﬁnal concentrations of 5 M and
00 g/mL, respectively. Medium and supplements
ere obtained from Gibco Invitrogen (Carlsbad, CA)
nd Sigma-Aldrich (St Louis, MO). The PBMCs were
ultivated for 4.5 hours, then harvested, washed, and
esuspended in PBS with 2% goat serum and 0.2%
odium azide. Cells were counted, the concentration
as adjusted to 1  106/mL, and the cells were cen-
rifuged at 800 rpm for 10 minutes. After removal of
he supernatant, the cells were resuspended in 100 L af mAb solution (concentration of 10 g/mL), incu-
ated on ice for 30 minutes, and then washed with
mL of PBS  2% goat serum and 0.2% sodium
zide. After centrifugation, the supernatant was re-
oved, and the cells resuspended in ﬂuorescein iso-
hiocyanate (FITC)-labeled goat anti-mouse second-
ry antibody solution (dilution 1:100; Jackson
mmunoResearch Laboratories, West Grove, PA), in-
ubated in the dark at 4°C for 30 minutes, washed, and
esuspended in 1 mL of PBS with 2% goat serum and
.2% sodium azide. The cells were analyzed using a
ACS-Calibur machine and Cell Quest Pro software
Becton Dickinson, Franklin Lakes, NJ). Correspond-
ng isotype controls were obtained from Dako North
merica (Carpinteria, CA).
ixed Leukocyte Reactions
Mixed leukocyte reactions (MLRs) were per-
ormed as described previously [10]. Puriﬁed anti-
D154 mAb 5c8 was added to the medium in a con-
entration of 10 g/mL for initial testing and in doses
ncreasing from 1 g/mL to 50 g/mL to determine
ose effects. CTLA4-Ig (courtesy of Dr. Richard Bo-
smenu, Repligen Corp, Waltham, MA) was used as a
ositive control, and the irrelevant mouse antibody
1A was used as a negative control.
harmacokinetic Studies
Three dogs received single intravenous (IV) doses
f anti-CD154 mAb 5c8 of 1, 5, and 10 mg/kg. These
ogs had not been previously exposed to mouse im-
unoglobulin. After injection, serial blood samples
ere obtained at 10 and 30 minutes; at 1, 2, 4, 6 and
hours; and at 1, 2, 3, 4, 5, 6, 7, 8, 10, and 13 days.
he blood was centrifuged and the serum immedi-
tely stored at 70°C.
ntibody Concentrations and Immune Responses
Serum concentrations of mAb 5c8 were measured
y enzyme-linked immunosorbent assay (ELISA).
rieﬂy, anti-mouse IgG–precoated 96-well plates
R&D Biosystems, Minneapolis, MN) were blocked
ith 5% chicken serum and 0.5% Tween 20 contain-
ng PBS and incubated with canine serum from
reated dogs (dilution: sample-dependent, 1:25000-1:
00). Bound 5c8 was detected by horseradish peroxi-
ase–conjugated goat anti-mouse IgG (HL; Pierce,
ockford, IL) as the secondary antibody. The color
eagent was 2,2=azino-bis (3-ethylbenzthiazoline-6-
ulfonic acid) (Sigma). Plates were read with a Vmax
icrotiter plate reader (Molecular Devices, Menlo
ark, CA) at 405 nm. Standard curves were estab-
ished with known concentrations of 5c8; sera ob-
ained from dogs before mAb infusion served as con-
rols. A similar procedure was used to detect canine
nti-5c8 antibodies, except the plates were coated with
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C. Jochum et al.166c8 solution, and bound antibodies were detected by
orseradish peroxidase–conjugated goat anti-dog IgM
-chain) and goat anti-dog IgG (HL chain) (Im-
unology Consultants Laboratory, Newberg, OR) to
istinguish between the 2 isotypes. Active pooled nor-
al dog serum served as a negative control. The
anine serum samples were diluted by 1:100.
ematopoietic Cell Transplantation
On days 6 and 5 before marrow transplanta-
ion, recipients were given 0.5 mg/kg ketorolac IV as
rophylaxis against thrombosis, as described for anti-
D154 5c8 treatment [11,12]. On day5, the animals
eceived 5 mg/kg of anti-CD154 5c8 IV. On day 4,
 107 donor PBMCs/kg were administered; half of
he cells were infused IV and the other half were given
ubcutaneously for optimal antigen presentation.
On day 0, recipients were given 1-Gy TBI and
onor marrow as described previously [2,13]. Marrow
rafts contained 2.26-8.08  108 nucleated cells
NCs)/kg (median, 4.22  108 NCs/kg). This is com-
arable to the cell doses used in previous studies, with
median of 4.0  108 total NCs/kg in the study with
SP and MMF [1] and 3.8 108 NCs/kg in the study
ith CSP and sirolimus [2]. The dogs received stan-
ard posttransplantation care. Immunosuppression
onsisted of CSP 15 mg/kg twice a day orally from day
1 to day 35 and MMF 10 mg/kg twice a day subcu-
aneously from day 0 to day 27. CSP levels were
easured once weekly, and results were used for CSP
ose adjustments. MMF doses were adjusted accord-
ng to clinical toxicity, which was mainly gastrointes-
inal.
ssessment of Chimerism
Hematopoietic engraftment was assessed by doc-
mentation of donor dinucleotide and tetranucleotide
ariable-number tandem repeat (VNTR) polymor-
hisms in granulocyte and mononuclear cells from
eripheral blood using a polymerase chain reaction
PCR)-based assay as described previously [14]. Sam-
les were drawn weekly for the ﬁrst 12 weeks and then
able 1. Results in Dogs Given DLA-Identical Littermate Marrow Gr
TBI Dose
(Gy)
Pretransplantation
Immunomodulation
Posttransplantation
Immunosuppression
2 None MMF  CSP
2 None SRL  CSP
1 None MMF  CSP
1 None SRL  CSP
1 ATG MMF  CSP
1 MTX  donor PBMCs MMF  CSP
1 CTLA4-Ig  donor PBMCs MMF  CSP
Conditioning consisted of either 1 or 2 Gy of TBI and posttranspl
(SRL). The P values refer to comparisons of current results witvery 2 weeks thereafter until 6 months posttransplan- .ation. PCR products were analyzed by gel electro-
horesis, and percentages of donor chimerism in the
ecipients were determined using Image-quant soft-
are (AMPL Software Pty Ltd, Turramurra, NSW,
ustralia) after autoradiography.
ntibody Concentrations and Immune Responses
On days 5, 4, and 0, and then weekly for the
rst 7-8 weeks posttransplantation, serum samples
ere obtained to determine mAb 5c8 serum concen-
rations and the dogs’ immune responses against the
ntibody.
tatistical Analysis
Responses between anti-CD154–treated MLR
ultures and controls were compared using the paired
tudent t test. The durations of engraftment among
urrent dogs were compared with those in historical
ontrols (Table 1) [2] using the log-rank test. Associ-
tions among transplanted marrow cell doses, donor
himerism levels at week 6, and duration of donor
himerism were evaluated using Spearman’s rank cor-
elation coefﬁcient. All reported P values were
-sided, and those .05 were considered signiﬁcant.
ESULTS
low Cytometry, MLR, Pharmacokinetic Studies,
nd Dog Anti-mAb 5c8 Responses
Figure 1 illustrates cross-reactivity of the anti-
D154 mAb 5c8 with activated canine lymphocytes
ompared with a murine isotype control antibody.
low cytometry results indicate nearly a log increase
n the intensity of binding of mAb 5c8 over the neg-
tive control. The MLR studies used cells from DLA-
ismatched dogs after addition of irrelevant antibody
1A, anti-CD154 mAb 5c8, or CTLA4-Ig at concen-
rations of 10 g/mL medium each (Figure 2). Anti-
D154 mAb 5c8 reduced the 3H-thymidine uptake to
5% compared with medium alone (P  .0001).
TLA4-Ig reduced the MLR response to 20% (P 
r Conditioning*
Sustained
graftment (%)
Median Time of
Rejection (Weeks) P Value References
11/12 (92) 12 .0373 [1]
6/7 (86) 11 [2]
0/6 (0) 10 .0014 [1]
0/5 (0) 9 [2]
1/5 (20) 9.5 .145 [13]
2/6 (33) 8 .315 [25]
4/6 (66) 14 .721 [3]
immunosuppression with CSP combined with MMF or sirolimus
in previous studies using the log-rank test.afts afte
En
antation0001). The difference in MLR reactivities between
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DLA-Identical Marrow Transplantation in Dogs 167Ab 5c8 and CTLA4-Ig was signiﬁcant (P  .04).
ncreasing the mAb 5c8 concentration beyond 10
g/mL did not further decrease 3H-thymidine uptake,
hereas 5 g/mL mAb 5c8 also led to signiﬁcant
LR suppression (P  .002; data not shown). A con-
entration of 1 g/mL did not signiﬁcantly decrease
H-thymidine uptake.
Ten minutes after each injection of mAb 5c8,
erum concentrations reached maximum levels of 9.7
g/mL (dog G397, 1 mg/kg dose), 84.6 g/mL (dog
229, 5 mg/kg dose), and 137.4 g/mL (dog G389,
0 mg/kg dose) (Figure 3A). These serum levels de-
lined rapidly within 24 hours, to 4.7 g/mL, 54.9
g/mL, and 76.8 g/mL, respectively, likely reﬂect-
ng distribution of the antibody. Serum levels contin-
ed to decline gradually over the ensuing days, fol-
igure 1. Distribution of PMA and ionomycin- activated canine
ymphocytes stained with FITC-labeled anti-CD154 antibody 5c8
solid line) and a mouse isotype control (dotted line). Events are gated
or living lymphocytes (vital stain: propidium iodide).
igure 2. MLR results. Shown are averages of 6 experiments, with
ach individual experiment done in triplicate. Anti-CD154 mAb
c8, irrelevant mAb 31A (negative control), and CTLA4-Ig (posi-
ive control) were added at concentrations of 10 g/mL each. The
aximum 3H-thymidine uptake of the medium control in each
xperiment was set at 100%. Error bars represent 1 standard devi-
tion. P values were calculated using the paired Student t test.
edium versus irrelevant mAb 31A, P  .14; medium versus 5c8,
 .0001; medium versus CTLA4Ig, P  .0001; mAb 5c8 versusTLA4Ig, P  .04.owed by rapid clearing of the mAb between days 8
nd 10. No side effects of the mAb injections were
een.
Anti-mAb 5c8 antibodies began to appear at days
-8 after injection, and their titers increased as mAb
c8 was cleared from the circulation (Figure 3B). The
mmune responses were predominantly of the IgG
sotype, with lesser contributions of IgM antibodies.
arallel ELISA testing on mAb 5c8– and mouse
gG2a–coated plates suggested that 2 animals had
ither pure (dog G397) or predominantly (dog G389)
nti-idiotype IgG-responses, whereas 1 animal had an
nti-mouse isotype response (dog G229).
ematopoietic Cell Transplantation
The 6 recipient dogs’ characteristics and outcomes
f HCT are summarized in Table 2. Figure 4 sum-
arizes the dogs’ serum concentrations of mAb 5c8
nd canine antibody responses against mAb 5c8. The
ormer ranged from 45 to 81 g/mL (median, 59
igure 3. (A) Serum concentrations of anti-CD154 mAb 5c8 in 3
ogs given 1, 5, and 10 mg mAb/kg. Concentrations were cal-
ulated against a standard of puriﬁed mAb 5c8. (B) Antibody
esponses to anti-CD154 mAb 5c8 in 3 dogs given 1, 5, and 10
g mAb/kg. IgG and IgM responses were assessed by isotype-
peciﬁc secondary antibodies.g/mL) on day 4 and from 24 to 48 g/mL (me-
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C. Jochum et al.168ian, 37 g/mL) on day 0. The antibody clearances
ere considerably slower than those seen in the phar-
acokinetic studies (days 35-52). Four dogs devel-
able 2. HCT Outcomes in 6 Dogs Given 5 mg/kg Anti-CD154 mAb
arrow Grafts*
Dog
ID
No.
Nucleated
Marrow Cells
( 108/kg) Toxicities
Maximum
Chimeris
Mononuclear
Cells G
487 3.32 GI† 9.4
496 7.84 GI, infection allergic
reaction to mAb 5c8
71.0
521 8.08 A 51.2
536 4.22 GI 24.5
577 2.26 GI, intussusception 10.2
579 3.59 GI, allergic reaction to
mAb 5c8
31.9
I indicates gastrointestinal.
MMF  CSP were administered after grafting.
GI toxicities usually manifested as diarrhea, nausea, or anorexia.
igure 4. (A) Serum concentrations of mAb 5c8 in the 6 dogs that
nderwent transplantation. Concentrations were calculated against
standard of puriﬁed mAb 5c8. (B) IgG antibody responses againstwAb 5c8, assessed by isotype-speciﬁc secondary antibodies.ped IgG anti-5c8 antibodies. In 3 of these 4 dogs,
ntibodies were detectable on the day of transplanta-
ion, with a second peak occurring after cessation of
he postgrafting immunosuppression. In 1 dog, anti-
Ab 5c8 antibodies appeared beyond day 35. No
orrelations between antibody response and duration
f hematopoietic engraftment were seen.
All 6 dogs exhibited prompt initial marrow en-
raftment. Both neutrophil and platelet counts
howed nadirs at around day 20 after HCT before
ventual blood count recovery occurred (Figure
A). Lymphocyte counts remained 1000/L be-
ween days 3 and 40 and then recovered. Peak donor
himerism levels were 10.8%-82.8% (median,
0.5%) for granulocytes (weeks 7-26; Figure 5B and
able 2) and 9.4%-71.0% (median, 28%) for mono-
uclear cells (weeks 4-26; Figure 5C and Table 2).
hree of the 6 dogs demonstrated graft rejection, at
eeks 9, 22, and 24 respectively. The remaining 3
ere stable respectively mixed donor/host chimeras
or 	26 weeks of follow-up. The median durations
f engraftment in the 6 dogs were signiﬁcantly
reater than those in 11 historical controls [1,2] not
iven pretransplantation treatment (P  .0014; log-
ank test; Table 1 and Figure 6) but were shorter
han those achieved with 2-Gy TBI. There were no
tatistically signiﬁcant differences between the cur-
ent results and those of 3 regimens that used treat-
ent before TBI with antithymocyte globulin, do-
or PBMCs, and methotrexate, or donor PBMCs
nd CTLA4-Ig (Table 1). The 50% cumulative rate
f engraftment was signiﬁcantly higher than the 0%
ate in historical controls that received no pretrans-
lantation treatment (P  .03; Fisher’s exact test;
able 1). High granulocyte chimerism levels at
d Donor PBMCs before 1-Gy TBI Conditioning and DLA-Identical
Cumulative
CSP/MMF Dosing
(% of Intended
Dose)
Rejection
(Week) Outcomeocytes
.8 100/79 Yes (22) Alive, autologous
recovery
.8 100/64 No Alive, mixed chimerism
.0 100/100 No Alive, mixed chimerism
.9 100/75 Yes (24) Alive, autologous
recovery
.9 89/79 Yes (9) Alive, autologous
recovery
.6 100/74 No Alive, mixed chimerism5c8 an
Donor
m (%)
ranul
10
82
73
33
28
66eek 6 correlated signiﬁcantly with sustained en-
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DLA-Identical Marrow Transplantation in Dogs 169raftment (Spearman’s rank correlation coefﬁ-
ient  0.8783; P  .033).
The hematologic and nonhematologic toxicities
ere mild and comparable to those seen in previous
tudies using 1-Gy TBI and postgrafting MMF and
SP [1,3,13]. The ﬁrst dog showed allergic reactions
o the mAb infusion, which resolved with diphenylhy-
ramine and hydration. Therefore, subsequent dogs
eceived diphenylhydramine 2.5 mg/kg IV 5 minutes
efore mAb infusion as prophylaxis against allergic
eactions. One dog (G577) developed an intussuscep-
igure 5. Hematologic changes in 6 dogs receiving DLA-identical
ittermate marrow grafts. (A) Median neutrophil, lymphocyte, and
latelet counts. (B) Donor granulocyte chimerism levels. (C) Donor
ononuclear cell chimerism levels.ion that was likely related to CSP and required sur- 2ical correction and suspension of postgrafting immu-
osuppression for 24 hours. GVHD was not observed
n any of the dogs.
ISCUSSION
The current study demonstrated that pretreat-
ent of recipients with the anti-CD154 mAb 5c8 and
onor PBMCs led to prolonged engraftment of DLA-
dentical marrow in dogs conditioned with 1-Gy TBI
nd treated with short courses of MMF and CSP after
ransplantation. However, sustained engraftment was
een only in half of the recipients. The results are
imilar to those seen in studies of mice [4,5], in which
niform engraftment depended on both the strain
ombinations used and total marrow cell doses in-
ected. A dose of 1  108 marrow cells (
4  109
ells/kg) resulted in 100% engraftment even in the
ost resistant mouse strain combination, whereas in-
ection of 0.5  108 marrow cells led to chimerism in
nly 68% of the mice [4]. Comparable marrow cell
oses could not be achieved in dogs. Of note, the 2
ogs with the highest marrow cell doses (7.84 and
.08  108 cells/kg) were among the 3 dogs that
xhibited stable engraftment for 	26 weeks.
Previous studies of marrow transplantation in
ice [4,5] and solid organ transplantation in nonhu-
an primates [15,16] used higher total doses of anti-
D154 mAb than those administered in the current
tudy. Only limited pharmacokinetic data for anti-
D154 mAb have been reported in the literature
17,18]. Two studies examined the pharmacokinetics
f humanized anti-CD154 mAbs (5c8 [17] and IDEC-
31 [17,18]) in monkeys. No antibody responses
igure 6. Kaplan-Meyer estimates of graft survival in the 6 dogs
retreated with anti-CD154 mAb 5c8 and donor PBMCs and 11
ontrol dogs that did not receive pretransplantation treatment. All
ogs were conditioned with 1-Gy TBI, received marrow grafts from
LA-identical littermates, and were given MMF or rapamycin for
8 days and CSP for 35 days posttransplantation.
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C. Jochum et al.170gainst these mAbs were detected in the primates. In
oth studies, the suppression of T-cell–dependent B-
ell responses against soluble antigens (tetanus toxoid
17] or ovalbumin [17,18]) were used to determine the
n vivo efﬁcacy of the antibodies. In both studies,
ingle 5-mg/kg doses of anti-CD154 mAb effectively
uppressed the antibody responses against the foreign
ntigens, although the humanized mAb 5c8 did not
esult in complete suppression, even at a mAb dose of
0 mg/kg. In the present study, complete MLR sup-
ression was not observed even with high doses of
Ab 5c8. We chose the smallest antibody dose for in
ivo studies that achieved serum antibody levels 	10
g/mL for at least 5 days. This was realizable with a
ingle mAb dose of 5 mg/kg IV, because the serum
oncentration of mAb 5c8 was 39 g/mL even 5 days
fter injection.
All dogs in the pharmacokinetic studies and 4 of
he 6 dogs in the transplantation study developed IgG
ntibody responses against mAb 5c8 beginning as
arly as 5 days after injection. The emerging canine
ntibodies likely determined the tempo of clearance of
Ab 5c8 from the circulation. The development of
gG responses without preceding IgM responses was
urprising, because the dogs had no known previous
xposure to mouse immunoglobulin. In 2 of the 3
ogs analyzed, anti-idiotype or idiotype-like antibod-
es were found. Unlike the mice, the dogs were not
aintained in pathogen-free conditions, which might
ave resulted in more educated immune systems
19,20].
The results achieved with CD154 blockade in
ogs were not signiﬁcantly different than those previ-
usly seen with B7-CD28 blockade using CTLA4-Ig
3]; both studies failed to accomplish uniform sus-
ained engraftment. Given the increasing number of
ewly discovered T-cell regulatory and costimulatory
olecules [21], it seems likely that the blockade of
nly one system might not have been sufﬁcient to
vercome host resistance after a low-intensity or very-
ow-intensity conditioning regimen. Perhaps combin-
ng anti-CD154 mAb and CTLA4-Ig might be syn-
rgistic or additive and lead to more uniform sustained
ngraftment, as has been described in murine models
f marrow and islet transplantation [22-24].
In conclusion, blocking the CD40–CD154 co-
timulatory signal was feasible and partially successful
n establishing sustained allogenic canine marrow
rafts after conditioning with only 1-Gy TBI. Canine-
peciﬁc molecules and combinations of different co-
timulatory blockers may be required for more uni-
orm success.
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